- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05809193
Investigation of the Effects of Family-Focused Therapy in the Early Period of Bipolar Disorder and Psychotic Disorder
Study Overview
Status
Intervention / Treatment
Detailed Description
In this study, the researcher's primary goal is to investigate the effects of family-focused therapy sessions on young people aged between 15 and 21. Subjects were referred to an early intervention center for psychotic and bipolar disorders. The target population of the study consists of the patients in remission after the episode of the illness.
Therapy sessions will be conducted in line with the manual for "Family Focused Therapy for High-Risk Adolescents and Young Adults for Bipolar Disorder or Psychosis" revised by Miklowitz et al. in 2018. FFT will be completed in nine sessions. The first module of the program consists of three sessions, which consists of group psychoeducation for the patients and families. The second and third modules also include three sessions in each to teach communication skills and problem-solving skills in individual therapy sessions including patients and their families. Sessions will be held once a week and completed in nine weeks.
Within the scope of this program, non-therapist clinicians will evaluate the participants' symptoms, psychosocial functioning, insight, and treatment compliance before and after the therapy sessions.
There are only a few previous studies investigating the effects of family therapy in early stages of bipolar disorder and psychotic disorder. According to the literature, no prior study compares the effects of FFT between BD and PD populations. This study is important in terms of developing effective strategies for management of psychosocial difficulties in early phases of BD and PDs.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Balcova
-
Izmir, Balcova, Turkey, 35330
- Dokuz Eylul University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Not be in an active phase of the illness
- Able to comply with the interviews
- The total score of the Hamilton Depression Rating Scale ≤ 21 points.
- The total score of the Young Mania Rating Scale ≤ 14 points.
- At least one family member with the capacity to read and write in Turkish
Exclusion Criteria:
- Neurological disorders and serious physical disease that affect cognitive functions
- The symptoms due to substance use or a medical illness
- Autism Spectrum Disorder
- Comorbid alcohol and substance abuse (except nicotine)
- Co-morbid psychiatric disorders except disruptive behavior disorders and anxiety disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Family-Focused Therapy
Bipolar Disorder and Psychotic Disorder
|
After the patient and family are informed, they are included in the therapy group on a voluntary basis. After evaluation by independent evaluators, therapy sessions are started by therapists. Session 1: Goal Setting, Treatment Overview, Symptoms, Vulnerability Stress Model Session 2: Stress and Coping Skills, Regulation of sleep habits, Relaxation exercises Session 3: Optimizing Family Support; Prevention Plan, Medication adherence Session 4: Overview of Communication Skills; Expressing Positive Feelings, Active Listening Session 5: Making Positive Requests for Change, Communication Clarity Session 6: Expressing Negative Feelings Session 7: Introduction to Problem Solving Skills Session 8 and 9: Problem Solving Skills, Termination of Treatment The same psychometric assessment will be repeated before and after FFT. Intra-group comparisons will be made. Also study groups will be compared using time by group interactions to investigate the differences in therapy response. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change from baseline to follow-up in Hamilton Depression Rating Scale (HDRS) scores
Time Frame: at baseline and at week 9
|
by independent clinician/ to the patient - HDRS is a clinician-administered scale that measures the severity of depression.
It contains 17 questions scored between 0-4.
The total score of the scale ranges from 0 to 51.
Cut-off points were determined as <7 normal, 8-13 mild, 14-18 moderate, 19-22 severe and >23 very severe.
|
at baseline and at week 9
|
|
The change from Personal and Social Performance Scale (PSP) scores
Time Frame: at baseline and at week 9
|
by independent clinician/ to the patient - The scale evaluates personal and social performance in 4 sub-dimensions; Socially useful activities, personal and social relationships, self-care, irritating and aggressive behavior.
6-point Likert-type rating (1=absent - 6=very severe) was used.
|
at baseline and at week 9
|
|
The change from Scale of Unawareness of Mental Disorder (SUMD) scores
Time Frame: at baseline and at week 9
|
by independent clinician/ to the patient - SUMD was developed by Amador et al in 1993 to evaluate insight in psychiatric disorders.
The Turkish reliability of this scale was determined by Bora E et al. (Bora et al. 2006).
The scale is scored between 1-5 points and consists of 3 general items: being aware of mental disorders, being aware of the effects of drugs, and being aware of the social consequences of the disorder.
High scores represent poor insight.
|
at baseline and at week 9
|
|
The change from baseline in Young Mania Rating Scale score
Time Frame: at baseline and at week 9
|
by independent clinician/ to the patient - The Young Mania Rating Scale (YMRS) is a likert-type scale developed to measure the severity of manic symptoms.
7 of 11 items are graded in the range of 0-4, and the other 4 items are graded in the range of 0-8 points.
Therapy sessions will be started if the Young Mania Rating Scale total score is ≤ 14 points.
In addition, measurements will be repeated at the end of therapy.
|
at baseline and at week 9
|
|
The change from baseline in Scale for the Assessment of Positive Symptoms (SAPS)
Time Frame: at baseline and at week 9
|
by independent clinician/ to the patient - This scale aims to measure severity of positive symptoms in schizophrenia.
It includes a total of 34 items in 4 subscales: hallucinations, delusions, bizarre behavior and positive formal thought disorder.
Measurements will be made at the beginning and the difference will be examined by repeating at the end of the sessions.
|
at baseline and at week 9
|
|
The change from baseline in Brief Negative Symptom Scale (BNSS)
Time Frame: at baseline and at week 9
|
by independent clinician/ to the patient - BNSS consists of 13 items and has six subscales: anhedonia, stress, asociality, avolition, blunt affectivity, and alogia.
The total score of the scale, which can range from 0 to 78, is obtained by summing the scores of 13 items.
Measurements will be made at the beginning and the difference will be examined by repeating at the end of the sessions.
|
at baseline and at week 9
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Coping Strategies Scale Brief Form (Brief COPE)
Time Frame: at baseline and at week 9
|
self report / to the patient - The Coping Strategies Short Form is the short form of the Coping Strategies (COPE) scale developed by Carver, Scheier, and Weintraub (1989), which measures people's different behaviors against stress, developed by Carver (1997).
Coping Strategies Short Form consists of 14 subscales.
It will be given at the beginning and at the end of the therapy sessions and the difference will be evaluated.
|
at baseline and at week 9
|
|
Shortened Level of Expressed Emotion Scale
Time Frame: at baseline and at week 9
|
self report / to the patient - The scale developed by Nelis et al. consists of 33 items measuring the perceived emotional expression of the most influential person in the participant's life in the last three months.
The three subscales of the scale are lack of emotional support, irritability and intrusiveness.
It will be given at the beginning and at the end of the therapy sessions and the difference will be evaluated.
|
at baseline and at week 9
|
|
World Health Organization Quality of Life Assessment (WHOQOL)
Time Frame: at baseline and at week 9
|
self report / to the patient and parent - The WHOQOL-BREF scale consists of a total of 26 questions, two questions about the general health, and 4 areas: physical health, psychological health, social relationships and environment.
It will be given at the beginning and at the end of the therapy sessions and the difference will be evaluated.
|
at baseline and at week 9
|
|
Mc Master Family Assessment Device
Time Frame: at baseline and at week 9
|
self report / to the patient and parent - The scale, which consists of seven subscales called Problem Solving, Communication, Roles, Affective Responsiveness, Affective Involvement, Behavior Control, and General Functioning, consists of 60 items.
The scale is scored over four options varying between one and four points.
Theoretically, two scores were accepted as a score distinguishing healthy and unhealthy functions.
It can be applied to all family members over the age of twelve and to the subject himself to evaluate family functions.
It will be given at the beginning and at the end of the therapy sessions and the difference will be evaluated.
|
at baseline and at week 9
|
|
Beck's Depression Inventory
Time Frame: at baseline and at week 9
|
self report / to parent - It is a widely used self-report scale developed by Beck in 1961.
The Beck's Depression Inventory consists of 21 items related to depressive symptoms such as pessimism, sense of failure, dissatisfaction, feelings of guilt, restlessness, fatigue, decreased appetite, indecision, sleep disturbance, and social withdrawal.
Each item gets a score between 0 and 3.
The highest possible score is 63.
|
at baseline and at week 9
|
|
Zarit Burden Interview
Time Frame: at baseline and at week 9
|
self report / to parent - The scale, which can be filled in by the caregivers themselves or by the researcher, consists of 22 statements that determine the effect of caregiving on the individual's life.
The scale has a Likert-type rating ranging from 0 to 4 as never, rarely, sometimes, often, or almost always.
|
at baseline and at week 9
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Neslihan Inal, M.D., Dokuz Eylul University Department of Child and Adolescent Psychiatry
- Study Director: Emre Bora, M.D., Dokuz Eylul University Department of Psychiatry
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022/11-07
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
Vielight Inc.Not yet recruitingBipolar Disorder (BD) | Bipolar | Bipolar Disorder DepressionCanada
-
ProgenaBiomeWithdrawnBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Xenon Pharmaceuticals Inc.RecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Xenon Pharmaceuticals Inc.Enrolling by invitationBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderUnited States
-
University of California, Los AngelesUniversity of Colorado, Denver; University of Pittsburgh; University of Cincinnati and other collaboratorsRecruitingAdolescents | Bipolar Disorder (BD) | Bipolar Disorder I or II | Bipolar Disorder NOS | Bipolar Spectrum DisorderUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
Babes-Bolyai UniversityRecruitingBipolar Disorder (BD)Romania
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Korea University Anam HospitalHucircadian; Korea University MedicineEnrolling by invitationMood Disorders | Bipolar Disorder (BD) | Depression - Major Depressive Disorder | Depression BipolarSouth Korea
Clinical Trials on Family-Focused Therapy
-
University Hospital, MontpellierTerminated
-
Stanford UniversityUniversity of ChicagoCompleted
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)CompletedPsychosisUnited States, Canada
-
University of GuelphRecruitingDepression | Anxiety | Behavior ProblemCanada
-
VU University of AmsterdamUtrecht UniversityRecruiting
-
University of California, Los AngelesStanford University; University of Colorado, BoulderCompletedBipolar Disorder | Major Depressive DisorderUnited States
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)CompletedGeneralized Anxiety Disorder | Social Phobia | Separation Anxiety DisorderUnited States
-
Sunnybrook Health Sciences CentreTerminated
-
University of Southern DenmarkUniversity Hospital, Gentofte, CopenhagenWithdrawn
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)CompletedBipolar DisorderUnited States